Avelumab and Merkel Cell Carcinoma: Examining the Scientific Evidence

From General Skin Health to Occupational Exposure Concerns

The legacy of general health and science information has long emphasized the importance of skin care and anti-aging practices, drawing public attention to the maintenance of skin integrity and the prevention of visible signs of aging. This foundational knowledge established a broad awareness of skin health as a component of overall well-being, often focusing on lifestyle factors and topical interventions. Within this context, the public has become increasingly attuned to the role of external agents—whether environmental or chemical—in influencing skin condition. As the discourse on skin health matures, it naturally extends beyond cosmetic concerns to encompass more profound questions about the biological impact of substances introduced into the body. This shift in perspective invites a closer examination of pharmaceutical agents, particularly those administered in clinical settings, and their potential long-term effects on skin tissue. One such agent is Avelumab, a therapeutic monoclonal antibody used in oncology. The transition from general health awareness to a focused inquiry on occupational exposure arises when considering the manufacturing and handling of this drug. Workers in pharmaceutical production environments may encounter Avelumab through inhalation or dermal contact, raising legitimate questions about the relationship between such exposure and the risk of developing Merkel Cell Carcinoma. This pivot from heritage health information to a specific occupational concern underscores the need for rigorous scientific investigation into causation.

Understanding Avelumab: Mechanism and Approved Use

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The scientific evidence connecting avelumab to Merkel cell carcinoma is not one of causation in the sense of the drug causing the disease. Rather, avelumab is a treatment for MCC. The query's framing of "avelumab Merkel cell carcinoma causation" may reflect a misunderstanding.

Risk Considerations and Immune-Related Adverse Events

However, there are important risk considerations related to avelumab therapy in MCC patients. Immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab does not cause MCC, it can trigger immune-related complications in patients already diagnosed with the disease. A more relevant risk narrative concerns the efficacy and limitations of avelumab in treating MCC. Despite the advances in systemic therapy for MCC, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have investigated subsequent therapies, such as combined ipilimumab plus nivolumab, in patients who are refractory to avelumab. In one multicenter study, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another study reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, the same study noted that for avelumab-refractory patients, alternative treatments are needed.

Timeline of Exposure and Harm in MCC Patients

Regarding causation-related considerations for affected patients, the timeline between avelumab exposure and documented harm is not straightforward because avelumab is used as a treatment, not a trigger, for MCC. The harm associated with avelumab in MCC patients is primarily related to lack of response or progression of the underlying disease. The JAVELIN Merkel 200 trial demonstrated that about one-third of patients respond, meaning two-thirds do not achieve a confirmed objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). For those who progress, the timeline from avelumab initiation to documented progression can vary, but studies indicate that approximately 50% of advanced MCC patients treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This progression is not caused by avelumab but reflects the aggressive nature of MCC and the limitations of current treatments. The adequacy of warnings regarding avelumab and Merkel cell carcinoma should be considered in the context of prescribing information. Avelumab's approval for metastatic MCC is based on clinical trial data, and its label includes warnings about immune-related adverse events, which are common to this drug class. However, the evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. Therefore, warnings about avelumab causing MCC would be inappropriate and unsupported by scientific evidence. The risk for patients is that avelumab may not be effective, and they may experience disease progression or immune-related side effects. Clinicians should monitor patients for irAEs and consider alternative therapies, such as ipilimumab plus nivolumab, for those who are refractory to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Conclusion: No Causal Link Between Avelumab and MCC Development

In summary, the scientific evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Instead, avelumab is a therapeutic agent used to treat MCC. The risks associated with avelumab in MCC patients include lack of response, disease progression, and immune-related adverse events. The timeline from exposure to harm is variable and depends on individual patient factors and disease characteristics. Warnings about avelumab should focus on its efficacy limitations and potential for irAEs, not on causation of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel cell carcinoma?

No, the scientific evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a treatment for MCC, not a cause. It is an immune checkpoint inhibitor used to treat metastatic MCC.

What are the risks of Avelumab therapy in MCC patients?

The risks include lack of response (approximately two-thirds of patients do not achieve a confirmed objective response), disease progression, and immune-related adverse events such as hypercalcaemia secondary to reactivation of sarcoidosis. Clinicians should monitor for these events and consider alternative therapies for refractory patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.